Abstract | PURPOSE: To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a Phase I study to model with parallel linear and nonlinear clearances. METHODS: Binding characteristics of MNRP1685A in different species were evaluated using surface plasmon resonance technology. PK profiles of MNRP1685A after single and/or multiple doses in different species were analyzed using population analysis. PK parameters were compared across species. RESULTS:
MNRP1685A binds to NRP1 in all four species tested. Consistent with the wide expression of NRP1, MNRP1685A demonstrated pronounced non-linear PK over a wide dose range. PK profiles are best described by a two-compartment model with parallel linear and nonlinear clearances. Model-derived PK parameters suggest similar in-vivo target expression levels and binding affinity to target across all species tested. However, compared to typical human/humanized mAbs, non-specific clearance of MNRP1685A was faster in mice, rats, and humans (60.3, 19.4, and 8.5 ml/day/kg), but not in monkeys (3.22 ml/day/kg). CONCLUSIONS: Monkey PK properly predicted the target-mediated clearance of MNRP1685A but underestimated its non-specific clearance in humans. This unique PK property warrants further investigation of underlying mechanisms.
|
Authors | Yan Xin, Shuang Bai, Lisa A Damico-Beyer, Denise Jin, Wei-Ching Liang, Yan Wu, Frank-Peter Theil, Amita Joshi, Yanmei Lu, John Lowe, Mauricio Maia, Rainer K Brachmann, Hong Xiang |
Journal | Pharmaceutical research
(Pharm Res)
Vol. 29
Issue 9
Pg. 2512-21
(Sep 2012)
ISSN: 1573-904X [Electronic] United States |
PMID | 22707361
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Neuropilin-1
- vesencumab
|
Topics |
- Animals
- Antibodies, Monoclonal
(immunology, pharmacokinetics)
- Humans
- Models, Biological
- Neuropilin-1
(immunology)
- Species Specificity
|